ENCORE
CompletedA study defining the performance of the HelioLiver test in people diagnosed with liver cancer across stages I to IV.
Learn how Helio is advancing cancer research through clinical studies and collaborations with leading partners.
We are proud to collaborate with organisations that share our mission and values. Today, we partner with leading medical institutions and research centres to advance early cancer detection.
Helio Genomics
We are dedicated to making accurate early detection available for more cancers. Helio is engaged in multiple prospective, multi-centre studies across the United States.
A study defining the performance of the HelioLiver test in people diagnosed with liver cancer across stages I to IV.
A multi-centre, prospective US study comparing the sensitivity and specificity of the HelioLiver test against ultrasound, in people at high risk of HCC due to cirrhosis.
A prospective R01 study sponsored by the NCI, with Mount Sinai and other US institutions, evaluating novel screening methods and biomarkers.
A multi-centre, prospective US study discovering new biomarkers across cancer types, including colon, lung, and breast.
A multi-centre, prospective US study developing and validating Helio's blood test in people at high risk of HCC, and in those already HCC-positive.
Helio is looking to partner with research and clinical organisations that care for people who have cancer or are at high risk of developing it. Leave us a message if you'd like to collaborate on upcoming clinical trials and research.